ClinicalTrials.gg
CompletedNCT02544763Updated Sep 28, 2022Results posted

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

A Phase 3 interventional study of GWP42003-P and Placebo in Tuberous Sclerosis Complex and Seizures, sponsored by Jazz Pharmaceuticals. Completed at 44 sites in 6 countries. Open to participants aged 1 Year to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
1 Year to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies in Tuberous Sclerosis with a site in United States — 8 open to participants now, 15 under way, 1 of them phase 3. Tuberous Sclerosis · United States.

Enrollment
2nd of 47
224 · median 52
Started
2016
with 4 others
Phase 3
10 of 63
none open now
Registered
30th of 63
by date
Lead sponsor
5 of 63
Jazz Pharmaceuticals

Among the 63 studies in Tuberous Sclerosis with a site in United States, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2016, is one of 10 in phase 3, and was the 30th registered.

Tuberous Sclerosis

115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.

Browse Tuberous Sclerosis studies →

Open to participants now

8 of the 63 studies in Tuberous Sclerosis with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Tuberous Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will receive 1 of 2 doses of GWP42003-P or matching placebo. The primary clinical hypothesis is that there will be a difference between GWP42003-P and placebo in their effect on seizure frequency.

03

Conditions studied

  • Tuberous Sclerosis Complex
  • Seizures
04

Who can participate

Ages eligible
1 Year to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a well-documented clinical history of epilepsy.
  • Participant has a clinical diagnosis of Tuberous Sclerosis Complex (TSC) according to the criteria agreed by the 2012 International TSC Consensus Conference.
  • All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for 1 month prior to screening and the participant is willing to maintain a stable regimen throughout the trial.

Key Exclusion Criteria:

  • Participant has a history of pseudo-seizures.
  • Participant has unstable medical conditions other than epilepsy.
  • Participant has an illness in the 4 weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator could affect seizure frequency.
  • Participant has undergone general anesthetic in the 4 weeks prior to screening or randomization.
  • Participant has undergone surgery for epilepsy in the 6 months prior to screening.
  • Participant is being considered for epilepsy surgery or any procedure involving general anesthesia.
  • Participant has been taking felbamate for less than 1 year prior to screening.
  • Participant is taking an oral mTOR inhibitor.
  • Participant has any known or suspected to cannabinoids or any of the of the Medicinal Product (IMP), such as sesame oil.
  • Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.
  • Participant is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid-based medications, within the 3 months prior to screening and is unwilling to abstain for the duration for the study.
  • Participant has tumor growth which, in the opinion of the Investigator, could affect the primary endpoint.
  • Participant has significantly impaired hepatic function at the screening or randomization visit
  • Participant has received an IMP within the 12 weeks prior to the screening visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    25 mg/kg/day GWP42003-P

    100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).

    Drug: GWP42003-P

  • Experimental
    50 mg/kg/day GWP42003-P

    100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).

    Drug: GWP42003-P

  • Placebo comparator
    Placebo

    Placebo oral solution matching 100 mg/mL GWP42003-P.

    Drug: Placebo

Interventions

  • Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

    Also known as: Cannabidiol, CBD

  • DrugPlacebo

    Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)

    TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.

    Time frame: Baseline; up to Week 16

Secondary outcomes

  1. Number of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)

    Treatment responders are defined as those participants with a ≥ 50% reduction in TSC-associated seizure frequency. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Participants who withdrew from the trial during the treatment period are considered non-responders.

    Time frame: Baseline; up to Week 16

  2. Change From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit

    The combined caregiver and participant summary uses either the caregiver or participant version if only one version was completed, or the caregiver version if both caregiver and participant versions were completed. The CGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)."

    Time frame: Baseline; up to Week 16

  3. Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)

    Total seizures included all seizure types combined. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.

    Time frame: Baseline; up to Week 16

  4. Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as an AE with a start date on or after the first dose of IMP during the Blinded Phase up to and including the date of first dose of the Open-label Extension (OLE) Phase (OLE Day 1).

    Time frame: up to approximately Week 22

07

Results

Posted Sep 23, 2020

Participant flow

Participant flow — Overall Study
MilestoneGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Started757376
Completed656175
Not completed10121
Withdrew: Adverse event880
Withdrew: Withdrawn by parent/guardian111
Withdrew: Met withdrawal criteria020
Withdrew: Physician decision010
Withdrew: Difficulties taking imp100

Outcome measures

PrimaryPercent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)

TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.

Time frame:
Baseline; up to Week 16
Reported as:
Median · percent change
Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)
percent changeGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)-43.36 (-67.8 to -13.6)-36.55 (-67.0 to -5.5)-20.08 (-47.1 to 3.1)
Statistical analysis
  • GWP42003-P 25 mg/kg/Day · Percentage reduction: 48.6 · 95% CI 40.4 to 55.8
  • GWP42003-P 50 mg/kg/Day · Percentage reduction: 47.5 · 95% CI 39.0 to 54.8
  • Placebo · Percentage reduction: 26.5 · 95% CI 14.9 to 36.5
  • GWP42003-P 25 mg/kg/Day vs Placebo · Mixed Models Analysis · p = =0.0009 · Treatment ratio: 0.699 · 95% CI 0.567 to 0.861
  • GWP42003-P 50 mg/kg/Day vs Placebo · Mixed Models Analysis · p = =0.0018 · Treatment ratio: 0.715 · 95% CI 0.580 to 0.881
SecondaryNumber of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)

Treatment responders are defined as those participants with a ≥ 50% reduction in TSC-associated seizure frequency. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Participants who withdrew from the trial during the treatment period are considered non-responders.

Time frame:
Baseline; up to Week 16
Reported as:
Count of participants · Participants
Number of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)
ParticipantsGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Responders272917
Non-responders484459
Statistical analysis
  • GWP42003-P 25 mg/kg/Day vs Placebo · Cochran-Mantel-Haenszel · p = =0.0692 · Odds ratio (or): 1.95 · 95% CI 0.95 to 4.00The p-value was calculated from a Cochran-Mantel-Haenszel test stratified by age group (1-6, 7-11, 12-17 and 18-65 years).
  • GWP42003-P 50 mg/kg/Day vs Placebo · Cochran-Mantel-Haenszel · p = =0.0245 · Odds ratio (or): 2.29 · 95% CI 1.12 to 4.67The p-value was calculated from a Cochran-Mantel-Haenszel test stratified by age group (1-6, 7-11, 12-17 and 18-65 years).
SecondaryChange From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit

The combined caregiver and participant summary uses either the caregiver or participant version if only one version was completed, or the caregiver version if both caregiver and participant versions were completed. The CGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question, to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)."

Time frame:
Baseline; up to Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit
units on a scaleGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Caregiver3.0 ± 1.343.1 ± 1.403.5 ± 0.93
Combined Caregiver and Participant3.0 ± 1.353.2 ± 1.453.5 ± 0.96
Participant3.3 ± 1.514.5 ± 1.732.8 ± 1.26
Statistical analysis
  • GWP42003-P 25 mg/kg/Day vs Placebo · nominal · p = =0.0074 · Odds ratio (or): 2.25 · 95% CI 1.24 to 4.07The global impression of change was analyzed using an ordinal logistic regression model with treatment group as a fixed factor.
  • GWP42003-P 50 mg/kg/Day vs Placebo · nominal · p = =0.0580 · Odds ratio (or): 1.77 · 95% CI 0.98 to 3.20The global impression of change is analyzed using an ordinal logistic regression model with treatment group as a fixed factor.
SecondaryPercent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)

Total seizures included all seizure types combined. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100.

Time frame:
Baseline; up to Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)
percent changeGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)-34.71 ± 46.150-35.14 ± 42.530-19.63 ± 35.137
Statistical analysis
  • GWP42003-P 25 mg/kg/Day · Percentage reduction: 0.519 · 95% CI 0.447 to 0.602
  • GWP42003-P 50 mg/kg/Day · Percentage reduction: 0.524 · 95% CI 0.452 to 0.607
  • Placebo · Percentage reduction: 0.731 · 95% CI 0.632 to 0.846
  • GWP42003-P 25 mg/kg/Day vs Placebo · Mixed Models Analysis · p = =0.0013 · Treatment ratio: 0.709 · 95% CI 0.576 to 0.873
  • GWP42003-P 50 mg/kg/Day vs Placebo · Mixed Models Analysis · p = =0.0018 · Treatment ratio: 0.716 · 95% CI 0.582 to 0.882
SecondaryNumber of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as an AE with a start date on or after the first dose of IMP during the Blinded Phase up to and including the date of first dose of the Open-label Extension (OLE) Phase (OLE Day 1).

Time frame:
up to approximately Week 22
Reported as:
Count of participants · Participants
Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)
ParticipantsGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE)791

Adverse events

Collected over up to approximately Week 22. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 25 mg/kg/Day0/75 (0%)16/75 (21.3%)66/75 (88%)
GWP42003-P 50 mg/kg/Day0/73 (0%)10/73 (13.7%)71/73 (97.3%)
Placebo0/76 (0%)2/76 (2.6%)68/76 (89.5%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
Alanine aminotransferase increasedInvestigations2/752/730/76
Aspartate aminotransferase increasedInvestigations2/752/730/76
Transaminases increasedInvestigations0/752/730/76
VomitingGastrointestinal disorders2/750/730/76
Gastroenteritis viralInfections and infestations2/750/730/76
Status epilepticusNervous system disorders2/750/731/76
Abdominal painGastrointestinal disorders0/751/730/76
DiarrhoeaGastrointestinal disorders0/751/730/76
GastroenteritisInfections and infestations0/751/730/76
LacerationInjury, poisoning and procedural complications0/751/730/76
Most frequent other events
Showing 10 of 66
Most frequent other events
EventGWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlacebo
DiarrhoeaGastrointestinal disorders23/7540/7319/76
SomnolenceNervous system disorders10/7519/737/76
Decreased appetiteMetabolism and nutrition disorders15/7517/739/76
Alanine aminotransferase increasedInvestigations7/7514/730/76
PyrexiaGeneral disorders14/7512/736/76
VomitingGastrointestinal disorders12/7513/737/76
Aspartate aminotransferase increasedInvestigations6/7512/730/76
Gamma-glutamyltransferase increasedInvestigations12/7510/730/76
NasopharyngitisInfections and infestations11/7511/7312/76
Upper respiratory tract infectionInfections and infestations7/757/7310/76

Baseline characteristics

Baseline data are reported for members of the Safety Analysis Set, comprised of participants randomized to treatment who received at least 1 dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)GWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlaceboTotal
Mean14.112 ± 10.813112.915 ± 8.532413.918 ± 10.630213.659 ± 10.0324
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlaceboTotal
Female32303193
Male434244129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlaceboTotal
White/Caucasian686566199
Black/African American2305
American Indian/Alaska Native1001
Asian1034
Biracial Causasian-African American1001
Latin1001
Arabic1001
Caucasian/Asian0101
Hispanic/Latino0202
Hispanic0134
Hispanic And Caucasian0011
Anglo Indian0011
Black, White, American Indian0011
Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures
Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures(seizures)GWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlaceboTotal
Mean77.95 ± 83.39092.95 ± 89.78289.22 ± 101.77886.66 ± 91.841
Number of Total Seizures
Number of Total Seizures(seizures)GWP42003-P 25 mg/kg/DayGWP42003-P 50 mg/kg/DayPlaceboTotal
Mean80.87 ± 84.676108.06 ± 115.699118.32 ± 211.868102.44 ± 148.495
08

Study locations

44 sites
  • UAB Epilepsy Center
    Birmingham, Alabama 35294, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • UCLA-Pediatric Neurology
    Los Angeles, California 90095, United States
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Pediatric Neurology
    Miami, Florida 33155, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Mid Atlantic Epilepsy & Sleep Centre
    Bethesda, Maryland 20817, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Minnesota Epilepsy Group, P.A
    Saint Paul, Minnesota 55102, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • NYU Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • WellSpan Paediatric Neurology
    Manchester, Pennsylvania 17345, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Texas Scottish Rite Hospital for Children
    Dallas, Texas 75104, United States
  • Cook Children's Health Care System
    Fort Worth, Texas 76104, United States
  • Paediatric Neurology
    Salt Lake City, Utah 84113, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Austin Health
    Heidelberg, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Australia
  • The Royal Melbourne Hospital
    Parkville, Australia
  • Sydney Children's Hospital
    Randwick, Australia
  • Erasmus MC/Sophia Children's Hospital
    Rotterdam, Netherlands
  • UMC Utrecht/ Wilhelmina, Kinderziekenhuis
    Utrecht, Netherlands
  • Vitamed Gałaj I Cichomski Spółka Jawna
    Bydgoszcz, Poland
  • Centrum Medyczne Plejady
    Kraków, Poland
  • Wojewódzki Szpital Specjalistyczny im S. K. Wyszyńskiego SPZOZ
    Lublin, Poland
  • Instytut "Pomnik - Centrum Zdrowia Dziecka"
    Warsaw, Poland
  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego w Warszawie
    Warsaw, Poland
  • Centrum Neuropsychiatrii "Neuromed"
    Wrocław, Poland
  • Centro Médico Teknon
    Barcelona, Spain
  • Clinical Research Unit
    Barcelona, Spain
  • Unitat d'Epilèpsia
    Barcelona, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Cardiff and Vale University Local Health Board
    Cardiff, United Kingdom
  • Children and Young Adults' Research Unit
    Cardiff, United Kingdom
  • NIHR Clinical Research Facility
    London, United Kingdom
  • St George's University Hospitals NHS Foundation Trust
    London, United Kingdom
09

References and documents

Publications

  • Wu JY, Cock HR, Devinsky O, Joshi C, Miller I, Roberts CM, Sanchez-Carpintero R, Checketts D, Sahebkar F. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6. Epilepsia. 2022 May;63(5):1189-1199. doi: 10.1111/epi.17199. Epub 2022 Mar 4. PubMed 35175622 ↗
  • Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia. 2022 Feb;63(2):426-439. doi: 10.1111/epi.17150. Epub 2021 Dec 27. PubMed 34957550 ↗
  • Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. PubMed 33346789 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Jan 2019, 33 months.

Results were first posted in Sep 2020, 1 year 8 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2015
First posted
Sep 9, 2015
StartActual
Apr 6, 2016
Primary completionActual
Jan 22, 2019
CompletionActual
Feb 26, 2019
Results delay requested
Jan 21, 2020
Results first posted
Sep 23, 2020
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02544763
Responsible party
Sponsor
First posted
Sep 9, 2015
Start date
Apr 6, 2016
Primary completion
Jan 22, 2019
Completion
Feb 26, 2019
Results posted
Sep 23, 2020
Last update
Sep 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion